These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 4042092)
1. Influence of measurement error on response rates. Warr D; McKinney S; Tannock I Cancer Treat Rep; 1985 Oct; 69(10):1127-32. PubMed ID: 4042092 [No Abstract] [Full Text] [Related]
2. An efficient design for phase III studies of combination chemotherapies. Ellenberg SS; Eisenberger MA Cancer Treat Rep; 1985 Oct; 69(10):1147-54. PubMed ID: 4042093 [No Abstract] [Full Text] [Related]
3. Response surface methodology and the design of clinical trials for the evaluation of cancer chemotherapy. Carter WH Cancer Treat Rep; 1985 Oct; 69(10):1049-53. PubMed ID: 4042084 [No Abstract] [Full Text] [Related]
4. Factorial designs for randomized clinical trials. Byar DP; Piantadosi S Cancer Treat Rep; 1985 Oct; 69(10):1055-63. PubMed ID: 4042085 [No Abstract] [Full Text] [Related]
5. International Clinical Trials in Radiation Oncology. Large field trials. Rubin P; Heilmann HP Int J Radiat Oncol Biol Phys; 1988; 14 Suppl 1():S65-76. PubMed ID: 3292484 [No Abstract] [Full Text] [Related]
6. Reflections on medical oncology: 25 years of clinical trials--where have we come and where are we going? Booth CM; Tannock I J Clin Oncol; 2008 Jan; 26(1):6-8. PubMed ID: 18165630 [No Abstract] [Full Text] [Related]
7. The scientific basis of clinical trials: statistical aspects. Gehan EA Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2587-90. PubMed ID: 9815661 [TBL] [Abstract][Full Text] [Related]
8. Standard of care for gastric cancer based on meta-analysis? Treading on thin ice or it is very nice! Ajani JA J Clin Oncol; 2006 Dec; 24(34):5473-4; author reply 5474-6. PubMed ID: 17135655 [No Abstract] [Full Text] [Related]
9. Is response rate relevant to the phase II trial design of targeted agents? Dowlati A; Fu P J Clin Oncol; 2008 Mar; 26(8):1204-5. PubMed ID: 18285601 [No Abstract] [Full Text] [Related]
10. Re: Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy? Bhutani M; Pathak AK J Natl Cancer Inst; 2008 Sep; 100(18):1334; author reply 1334-5. PubMed ID: 18780866 [No Abstract] [Full Text] [Related]
11. Sentinel lymph node sampling and analysis in colon cancer: what is the question? Pocard M; Van den Eynde M; Goere D; Boige V; Malka D J Clin Oncol; 2006 Aug; 24(22):3712-3; author reply 3713-4. PubMed ID: 16877744 [No Abstract] [Full Text] [Related]
12. What can we learn from phase II adjuvant trials in melanoma? Keilholz U; Suciu S; Eggermont AM Br J Cancer; 2000 Jul; 83(1):6-7. PubMed ID: 10883660 [No Abstract] [Full Text] [Related]
13. Clinical trial design in metastatic breast cancer: a commentary. Levine M Can J Oncol; 1995 Dec; 5 Suppl 1():40-2. PubMed ID: 8853523 [TBL] [Abstract][Full Text] [Related]
16. Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer. Nagourney RA Gynecol Oncol; 2000 Jan; 76(1):143. PubMed ID: 10620464 [No Abstract] [Full Text] [Related]
17. Chemotherapy for adult soft tissue sarcoma. Does it work? Saeter G Acta Orthop Scand Suppl; 1997 Feb; 273():139-44. PubMed ID: 9057605 [No Abstract] [Full Text] [Related]
18. [Chemotherapy of primary and metastasizing breast cancer]. Hofmann V; Martz G Gynakol Rundsch; 1984; 24 Suppl 1():78-86. PubMed ID: 6394442 [No Abstract] [Full Text] [Related]
19. Negative data from lung cancer trial may change practice guidelines, study designs. McNeil C J Natl Cancer Inst; 2006 Nov; 98(21):1518-20. PubMed ID: 17077353 [No Abstract] [Full Text] [Related]
20. Chemotherapy for head and neck cancer. Tannock IF J Otolaryngol; 1984 Apr; 13(2):99-104. PubMed ID: 6202878 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]